Naiemian et al. Diabetol Metab Syndr (2020) 12:65 https://doi.org/10.1186/s13098-020-00564-w Diabetology & Metabolic Syndrome RESEARCH Open Access Serum concentration of asprosin in new-onset type 2 diabetes Shakiba Naiemian1, Mohsen Naeemipour2, Mehdi Zarei3, Moslem Lari Najaf4, Ali Gohari2, Mohammad Reza Behroozikhah2, Hafez Heydari2* and Mohammad Miri5* Abstract Background: Asprosin, a newly identifed adipokine, is pathologically increased in individuals with insulin resist- ance. However, the available evidence on the association of asprosin and type 2 diabetes mellitus (T2DM) status is still scarce. Therefore, this study aimed to determine the relationship between serum concentrations of asprosin and T2DM status. Methods: This observational study was performed based on 194 adults (97 newly diagnosed T2DM and 97 healthy individuals). Anthropometric and biochemical variables were determined in all participants. Serum concentrations of asprosin were measured using enzyme-linked immunosorbent assay (ELISA). Results: In patients with T2DM, the serum concentrations of asprosin were signifcantly higher than the healthy con- trols (4.18 [IQR: 4.4] vs. 3.5 [IQR: 1.85], P < 0.001). The concentrations of asprosin were signifcantly correlated with body mass index (BMI) and fasting blood glucose (FBG) in healthy subjects and with BMI, FBG, hemoglobin A1c (HbA1c), homeostatic model assessment of insulin resistance (HOMA-IR), and quantitative insulin check index (QUICKI), triacyl- glycerol (TAG) and total cholesterol/high-density lipoprotein cholesterol (TC/HDL-C) ratio in the T2DM group. In fully adjusted model, the odds ratio (OR) of T2DM with serum concentrations of asprosin was approximately 1.547 (95% CI 1.293–1.850, P < 0.001) compared to the control group. Multiple stepwise regression analysis indicated that FBG and HOMA-IR were independently associated with asprosin in T2DM. Conclusion: Our fndings indicated that serum concentrations of asprosin are increased in patients with T2DM. Also, asprosin is correlated with insulin resistance and TC/HDL-C ratio (atherosclerotic risk factor of cardiovascular diseases) in patients with T2DM. Keywords: Diabetes mellitus, Asprosin, Adipokine, Insulin resistance Background However, the mechanisms that link these conditions are Obesity is a strong risk factor of type 2 diabetes mellitus not fully understood [3]. Improving our knowledge about (T2DM) [1]. Te global growth of obesity largely explains underlying mechanisms can lead to the identifcation and the reason behind the dramatic increase in the incidence development of new treatment options. and prevalence of T2DM over the past 20 years [2]. Adipokines are cytokines secreted from adipose tis- sue, which afect a broad spectrum of biological pro- cesses [4–7]. Some of these adipokines, such as resistin *Correspondence: [email protected]; [email protected] 2 Cellular and Molecular Research Center, Sabzevar University of Medical and leptin, antagonize insulin function in peripheral tis- Sciences, Sabzevar, Iran sues, especially in the liver and skeletal muscles, which 5 Non-Communicable Diseases Research Center, Department leads to insulin resistance [7–10]. In contrast, adiponec- of Environmental Health, School of Public Health, Sabzevar University of Medical Sciences, Sabzevar, Iran tin increases insulin sensitivity [11, 12]. Te balance Full list of author information is available at the end of the article between adipokines is thought to play an important role © The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/ zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Naiemian et al. Diabetol Metab Syndr (2020) 12:65 Page 2 of 8 in regulating insulin sensitivity [13]. Asprosin, a new adi- consumption, and smoking. Demographic information pokine, was identifed in 2016 by Romere.et al. [14]. Tis and lifestyle data were collected through a pre-designed adipokine is produced in response to starvation in adi- questionnaire by face to face interview. pocytes due to the breakdown of the C-terminal domain of profbrillin [14]. Asprosin rapidly releases glucose from liver cells by activating the G protein-cAMP-PKA Diagnostic criteria pathway [14]. Te olfactory receptor (OLFR734) acts as NGT and T2DM were diagnosed in 2014, accord- a receptor for asprosin in hepatocytes and is involved in ing to American Diabetes Association’s (ADA) recom- hepatic glucose production [15]. Olfr734 knockout mice mended criteria [26]. Subjects with fasting blood glucose have been shown a poor response to asprosin, low cAMP (FBG) ≥ 126 mg/dL, or hemoglobin A1c (HbA1c) ≥ 6.5%, and glucose production, and increased insulin sensitiv- or oral glucose tolerance test (OGTT) 2 h post-load ity [16]. Some studies have shown that serum concen- plasma glucose ≥ 200 mg/dL were considered as T2DM tration of asprosin is associated with insulin sensitivity patients. Subjects with FBG < 110 mg/dL, HbA1c < 5.7% [15, 17–20]. Injection of recombinant asprosin increases and OGTT-2 h post-loading plasma glucose < 140 mg/dL glucose and causes hyperinsulinemia, while injection of were considered as the control group. Hypertension was anti-asprosin antibodies improves glucose tolerance and defned as systolic blood pressure ≥ 140 mmHg or a dias- insulin resistance [14]. Elevated serum asprosin concen- tolic blood pressure ≥ 90 mmHg. trations are pathophysiologically in patients with meta- bolic syndrome [14]. Te association between asprosin and T2DM has been investigated in some studies [19– Anthropometric data collection 21]; however, for two major reasons, more evidence is Body weight and height were measured by a trained needed to confrm the role of asprosin in the develop- nurse. Body mass index (BMI) (kg/m2) was calculated by ment of T2DM. Firstly, ethnic variation usually afects dividing weight (kg) by height in squared meters (m 2). adipokines concentrations. Te results of studies carried Before each person’s blood pressure was measured, they out in diferent populations suggest that inconsistent rested for at least 10 min. Blood pressure was measured results may be obtained when adipokines are examined three times, and the mean of these values was considered in diferent populations [22–25]. Secondly, some of the as blood pressure. contradictory results are observed regarding the correla- tion of asprosin with lipid metabolism in previous studies [15, 20, 21]. Biochemical measurements Terefore, this observational study was designed to Blood samples were collected after at least 12 h over- compare the serum concentration of asprosin in new- night fasting between 07:30 -08:30 a.m. Blood samples onset T2DM patients with healthy subjects. were transferred to the laboratory in serum separator tubes with clot activator in less than 2 h. Glucose, tria- Materials and methods cylglycerol (TAG), total cholesterol (TC) were measured Subjects using enzymatic assays (Pars Azmoon, Tehran, Iran), and All participants of this observational study signed a high-density lipoprotein cholesterol (HDL-C) concentra- consent form approved by the Ethics Committee of tion was measured using a direct method (Pars Azmoon, Sabzevar University of Medical Sciences (Code of Eth- Tehran, Iran). Low-density lipoprotein cholesterol (LDL- ics: IR.MEDSAB.REC.1398.39) before including to C) concentration was calculated using the Friedewald study. From August to December 2018, 97 newly diag- formula [27]. Insulin was assessed using enzyme-linked nosed patients with T2DM (50 male and 47 female) immunosorbent assay (ELISA) kit (monobind Inc., USA). were recruited from the Diabetes Center of Vasei Hos- HbA1c concentration was measured using standard pital (Sabzevar, Iran). Over the same period, 97 healthy methods by PishtazTeb kit. Sera were stored at − 80 °C subjects with normal glucose tolerance (NGT) (50 male until subsequent analysis. Te homeostatic model assess- and 47 female) were selected as healthy controls in con- ment of insulin resistance (HOMA-IR), HOMA-β, sultation with a specialist physician. Inclusion criteria HOMA-S and quantitative insulin check index (QUICKI) for the T2DM group were: having T2DM, no treatment were used as insulin resistance and insulin sensitivity for diabetes, including drugs that afect glucose toler- indices, respectively. Tese indices were calculated using ance and insulin release, dietary control, exercise therapy. HOMA2-calculator (available at https ://www.dtu.ox.ac. Exclusion criteria were: obesity (BMI > 30 kg/m2), cancer, uk/homac alcul ator/) and QUICKI calculator online soft- thyroid disorders, liver disease, infection,